Edition:
United States

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

4.22USD
1:43pm EDT
Change (% chg)

$0.08 (+1.81%)
Prev Close
$4.15
Open
$4.15
Day's High
$4.25
Day's Low
$4.10
Volume
22,534
Avg. Vol
56,250
52-wk High
$8.35
52-wk Low
$3.95

Latest Key Developments (Source: Significant Developments)

Sorrento, Wildcat announce resolution
Monday, 20 Mar 2017 08:00am EDT 

Sorrento Therapeutics Inc : Sorrento and Wildcat announce resolution . Sorrento Therapeutics - reached mutual resolution with wildcat capital with respect to Wildcat's seeking of inspection of co's private placement . Sorrento Therapeutics - co and Wildcat have engaged in talks relating to steps needed to undertake in order to increase Sorrento's shareholder value . Sorrento Therapeutics Inc - as part of its core immuno-oncology business, sorrento is preparing to file an IND for at least one car-T phase I study .Sorrento Therapeutics Inc - Sorrento makes no admission of liability or wrongdoing in connection with Wildcat's inspection demand.  Full Article

Sorrento Therapeutics files for non-timely 10-K
Thursday, 16 Mar 2017 06:19am EDT 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc files for non-timely 10-K - SEC filing . Sorrento Therapeutics - as a result of acquisitions, other one-time items occurring late in Q4 2016, it is unable to file form 10-K within prescribed time period .Sorrento Therapeutics - will require additional time to ensure adequate disclosure of certain information required to be included in the form 10-K.  Full Article

Sorrento Therapeutics unit says key endpoints met in EU Pivotal Bioequivalence Clinical Study for ZTlido
Monday, 9 Jan 2017 09:00am EST 

Sorrento Therapeutics Inc - : Sorrento subsidiary, Scilex Pharmaceuticals, announces key endpoints met in the European Union Pivotal Bioequivalence Clinical Study for its lead product, ZTlido™ .Sorrento Therapeutics Inc- Marketing Authorization Application is expected to be filed in mid-2017 for ZTlido.  Full Article

Sorrento Therapeutics' study for ztlido meets primary endpoint
Monday, 5 Dec 2016 07:00am EST 

Sorrento Therapeutics Inc : Sorrento Therapeutics Inc - study for lead investigational product, ztlido has met a primary endpoint . Sorrento subsidiary, Scilex Pharmaceuticals announces key endpoints met in pivotal bioequivalence clinical study for its lead product, ztlido .Scilex Pharmaceuticals Inc - full data will be resubmitted to FDA as part of 505(B)(2) new drug application (NDA) in mid-2017.  Full Article

Sorrento Therapeutics files for resale of up to 1.2 mln shares of co's common stock by selling stockholders
Friday, 2 Dec 2016 05:38pm EST 

Sorrento Therapeutics Inc :Sorrento Therapeutics files for resale of up to 1.2 million shares of co's common stock by selling stockholders - SEC filing.  Full Article

Scintilla Pharma, a unit of Sorrento Therapeutics, to buy Semnur Pharma
Monday, 15 Aug 2016 06:34pm EDT 

Sorrento Therapeutics : Scintilla will pay semnur an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of sorrento . Scintilla pharmaceuticals,a subsidiary of sorrento therapeutics, inc., to acquire semnur pharmaceuticals .Additional cash consideration of up to $140 million may be paid by scintilla to semnur upon achievement of certain milestones.  Full Article

Scintilla to acquire Scilex Pharmaceuticals
Monday, 8 Aug 2016 09:00am EDT 

Scintilla Pharmaceuticals Inc: In consideration for deal, Scilex equity holders to receive up to $70 million in stock of Scintilla, after next equity financing of Scintilla . Has entered into a binding term sheet to acquire Scilex Pharmaceuticals, Inc .Acquisition is contingent upon completion of each parties' due diligence and other customary closing conditions.  Full Article

Sorrento Therapeutics to form JV with Cha Biotech to develop and commercialize natural killer cell therapies
Tuesday, 2 Aug 2016 09:00am EDT 

Sorrento Therapeutics Inc : Jv covers products on a global basis with exception of greater chinese market . To get exclusive license to develop cbt's novel investigator-initiated trial stage akc technology in major territories . Will also gain access to akc technology for use outside jv alone or with any other sorrento products . Sorrento to form joint venture with Cha Biotech to develop and commercialize natural killer cell therapies .Both cbt and sorrento will make contributions of $2 million to jv.  Full Article

Sorrento, Servier enter exclusive worldwide license, collaboration agreement
Monday, 11 Jul 2016 09:00am EDT 

Sorrento Therapeutics : Sorrento and Servier enter into exclusive worldwide license and collaboration agreement for development and commercialization of anti-PD-1 antibody . Financial terms of agreement include, among other things, a non-refundable upfront payment to Sorrento of EUR 25 million . May also receive development milestone payments for initial product and each additional product . May receive up to EUR 710 million in payments based on commercial sales milestones .To be entitled to receive royalties on sales of commercialized products ranging from high single-digit to double-digit percentages.  Full Article

Sorrento Therapeutics files for stock shelf of up to $176.6 mln - SEC Filing
Wednesday, 29 Jun 2016 04:58pm EDT 

Sorrento Therapeutics Inc :Says files for stock shelf of up to $176.6 million with U.S. SEC - SEC Filing.  Full Article

More From Around the Web

BRIEF-Sorrento, Wildcat announce resolution

* Sorrento Therapeutics - reached mutual resolution with wildcat capital with respect to Wildcat's seeking of inspection of co's private placement